After Hours Summary: NSA +4% on S&P SmallCap 600 addition news, WDC -2% following guidance (STX also lower)After Hours Gainers:
Companies trading higher in after hours in reaction to news: TOPS +30.9% (higher after announcing financial information after reverse stock split on June 23), NSA +4% (will replace Blackbaud in the S&P SmallCap 600), RAD +3.7% (continued strength on potential WBA / RAD FTC approval), THC +3.4% (following CBO score on Better Care Reconciliation Act of 2017 - Senate healthcare bill), KMPH +2.9% (announces patent for KP746), AMRN +2.9% (attributed to positive analyst comments), ESPR +1.7% (says the FDA recently confirmed the regulatory pathway to approval for the once-daily, oral combination pill of bempedoic acid 180 mg and ezetimibe 10 mg), AHH +1.2% (Pres/CEO disclosed purchase of 10000 shares worth approx $134K)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: WDC -2.2%
Companies trading lower in after hours in reaction to news: FNJN -10.2% (commenced an underwritten registered public offering of common stock), RGEN -6% (Repligen commences underwritten public offering of $100 mln in shares of its common stock), RGEN -6% (light volume; commences underwritten public offering of $100 mln in shares of common stock), NEOS -4.1% (proposed offering of common stock), ARR -3.7% (commences underwritten public offering of 4.5 mln shares of common stock), BLUE -2.1% (announces topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study evaluating Lenti-D in boys under 18 years old with cerebral adrenoleukodystrophy; commences underwritten public offering of $350 mln of its common stock), STX -2.1% (following WDC guidance)
![]()
In reaction to strong earnings/guidance:
- N/A
- RIO +0.6% (Rio Tinto confirms Yancoal as the preferred buyer of its thermal coal assets in Australia)
- SRNE +15.9% (successful Phase 1 / 2 pharmacokinetic bridging trial of the lead product SP-102)
- STOR +8.9% (announces that Berkshire Hathaway (BRK.A/B) has invested $377 mlnin the company, representing 9.8% of total shares outstanding)
- CBIO +4.9% (positive preclinical results of CB 2679d/ISU304)
- AVEO +4.8% (continued strength)
- TGTX +3.7% (recaps preliminary results from its ongoing Phase 2 study of TG-1101)
- CNAT +3.7% (confirms being granted Orphan Drug Designation by the FDA for IDN-7314)
- P +2.5% (CEO Tim Westergren plans to leave the company, according to ReCode)
- AMD +1.3% (continued strength following last weeks 25% rise)
- MOMO +1.1% (continued strength)
- PTLA +4.1% (target raised to $70 from $50 at Morgan Stanley)
- MU +2.1% (target raised to $40 from $32.50 at Wells Fargo)
- CS +1.6% (resumed with a Overweight at JP Morgan)
- COH +1.6% (upgraded to Buy from Neutral at Buckingham Research)
- UBS +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- COST +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
In reaction to disappointing earnings/guidance:
- N/A
- SSRI -3.6%, GFI -3.6%, GOLD -1.9%, NEM -1.9%, RGLD -1%
- NEOT -69.8% (announces top-line results for Phase 2 proof-of-concept study of LIPO-202)
- MTNB -48.7% (topline data from its Phase 2 safety, tolerability and efficacy study of MAT2203 did not meet primary endpoint)
- DRYS -9.8% (provides Kalani Investments update)
- AMAG -7.4% (FDA Filing Acceptance of Supplemental NDA for Makena subcutaneous auto-injector; reaffirms 2017 financial guidance)
- AGIO -6.9% (reports new data from DRIVE PK study; Program on track to enter global pivotal development in 1H18)
- SGEN -6.7% (Seattle Genetics and Takeda Pharmaceutical (TKPYY) announce that the Phase 3 ECHELON-1 clinical trial met its primary endpoint)
- DMRC -3.4% (to sell 500,000 common shares in a registered direct offering to a certain investor at a price of $35.55 per share)
- BBRY -1.3% (continued weakness)
- SSYS -2.8% (downgraded to Sell from Neutral at Goldman)
- INTU -0.9% (downgraded to Neutral from Buy at Citigroup)
- Reports Q3 (May) earnings of $0.56 per share, excluding non-recurring items, in-line with the single analyst estimate of $0.56; revenues rose 35.5% year/year to $477 mln.
- Preannonced Q3 adj. EPS $0.52-0.56 vs. $0.42 consensus on June 15.
- "Our third quarter results benefited from our continued focus on profitable growth. In both our Auto and Metals Recycling and our Steel Manufacturing Businesses, higher volumes and operating leverage from our multi-year productivity initiatives drove increased operating income," commented Tamara Lundgren, President and Chief Executive Officer. "Through the first nine months of this year, we have achieved our best earnings performance since fiscal 2012." "Our balance sheet continued to strengthen as we generated strong operating cash flow, driven primarily by higher profitability and also by lower working capital as compared to the second quarter. This enabled us to reduce debt while continuing to invest in our operations and to return capital to our shareholders."